Top

Published in:

Open Access 01-09-2016 | Preeclampsia (V Garovic, Section Editor)

Preeclampsia and Extracellular Vesicles

Authors: Sarwat I. Gilani, Tracey L. Weissgerber, Vesna D. Garovic, Muthuvel Jayachandran

Published in: Current Hypertension Reports | Issue 9/2016

Abstract

Preeclampsia is a hypertensive pregnancy disorder characterized by development of hypertension and proteinuria after 20 weeks of gestation that remains a leading cause of maternal and neonatal morbidity and mortality. While preeclampsia is believed to result from complex interactions between maternal and placental factors, the proximate pathophysiology of this syndrome remains elusive. Cell-to-cell communication is a critical signaling mechanism for feto-placental development in normal pregnancies. One mechanism of cellular communication relates to activated cell-derived sealed membrane vesicles called extracellular vesicles (EVs). The concentrations and contents of EVs in biological fluids depend upon their cells of origin and the stimuli which trigger their production. Research on EVs in preeclampsia has focused on EVs derived from the maternal vasculature (endothelium, vascular smooth muscle) and blood (erythrocytes, leukocytes, and platelets), as well as placental syncytiotrophoblasts. Changes in the concentrations and contents of these EVs may contribute to the pathophysiology of preeclampsia by accentuating the pro-inflammatory and pro-coagulatory states of pregnancy. This review focuses on possible interactions among placental- and maternal-derived EVs and their contents in the initiation and progression of the pathogenesis of preeclampsia. Understanding the contributions of EVs in the pathogenesis of preeclampsia may facilitate their use as diagnostic and prognostic biomarkers.

Roberts JM, August PA, Bakris G, Barton JR, Bernstein IM, Druzin M et al. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122(5):1122–31. doi:10.1097/01.AOG.0000437382.03963.88.

Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2013;170(1):1–7. doi:10.1016/j.ejogrb.2013.05.005.CrossRefPubMed

Ananth CV, Keyes KM, Wapner RJ. Pre-eclampsia rates in the United States, 1980–2010: age-period-cohort analysis. BMJ. 2013;347:f6564. doi:10.1136/bmj.f6564.CrossRefPubMedPubMedCentral

Xiong X, Demianczuk NN, Saunders LD, Wang FL, Fraser WD. Impact of preeclampsia and gestational hypertension on birth weight by gestational age. Am J Epidemiol. 2002;155(3):203–9.CrossRefPubMed

5.••

Myatt L, Redman CW, Staff AC, Hansson S, Wilson ML, Laivuori H, et al. Strategy for standardization of preeclampsia research study design. Hypertension. 2014;63(6):1293–301. doi:10.1161/HYPERTENSIONAHA.113.02664. This article describes methods to standardize the types of preeclampisa for research.CrossRefPubMed

Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol. 2013;209(6):544.e1–e12. doi:10.1016/j.ajog.2013.08.019.CrossRef

7.••

Roberts JM, Lain KY. Recent Insights into the pathogenesis of pre-eclampsia. Placenta. 2002;23(5):359–72. doi:10.1053/plac.2002.0819. This article describes the properties and functions of extracellular vesicles.CrossRefPubMed

Jauniaux E, Hempstock J, Greenwold N, Burton GJ. Trophoblastic oxidative stress in relation to temporal and regional differences in maternal placental blood flow in normal and abnormal early pregnancies. Am J Pathol. 2003;162(1):115–25. doi:10.1016/S0002-9440(10)63803-5.CrossRefPubMedPubMedCentral

9.••

Burton GJ, Woods AW, Jauniaux E, Kingdom JC. Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. Placenta. 2009;30(6):473–82. doi:10.1016/j.placenta.2009.02.009. This article describes the generation, secretion and interactions of extracellular vesicles.CrossRefPubMedPubMedCentral

10.

Yanez-Mo M, Siljander PR, Andreu Z, Zavec AB, Borras FE, Buzas EI, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015;4:27066. doi:10.3402/jev.v4.27066.CrossRefPubMed

11.

EL Andaloussi S, Mager I, Breakefield XO, Wood MJ. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013;12(5):347–57. doi:10.1038/nrd3978.CrossRef

12.

Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30:255–89. doi:10.1146/annurev-cellbio-101512-122326.CrossRefPubMed

13.

Anderson HC, Mulhall D, Garimella R. Role of extracellular membrane vesicles in the pathogenesis of various diseases, including cancer, renal diseases, atherosclerosis, and arthritis. Lab Investig. 2010;90(11):1549–57. doi:10.1038/labinvest.2010.152.CrossRefPubMed

14.

Gould SJ, Raposo G. As we wait: coping with an imperfect nomenclature for extracellular vesicles. J Extracell Vesicles. 2013;2. doi:10.3402/jev.v2i0.20389.

15.

Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ. 2005;330(7491):565. doi:10.1136/bmj.38380.674340.E0.CrossRefPubMedPubMedCentral

16.

Oteng-Ntim E, Meeks D, Seed PT, Webster L, Howard J, Doyle P, et al. Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: systematic review and meta-analysis. Blood. 2015;125(21):3316–25. doi:10.1182/blood-2014-11-607317.CrossRefPubMed

17.

Stepanian A, Bourguignat L, Hennou S, Coupaye M, Hajage D, Salomon L, et al. Microparticle increase in severe obesity: not related to metabolic syndrome and unchanged after massive weight loss. Obesity (Silver Spring). 2013;21(11):2236–43. doi:10.1002/oby.20365.CrossRef

18.

Sabatier F, Darmon P, Hugel B, Combes V, Sanmarco M, Velut JG, et al. Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. Diabetes. 2002;51(9):2840–5.CrossRefPubMed

19.

Tramontano AF, Lyubarova R, Tsiakos J, Palaia T, Deleon JR, Ragolia L. Circulating endothelial microparticles in diabetes mellitus. Mediat Inflamm. 2010;2010:250476. doi:10.1155/2010/250476.CrossRef

20.

Zhang X, McGeoch SC, Johnstone AM, Holtrop G, Sneddon AA, MacRury SM, et al. Platelet-derived microparticle count and surface molecule expression differ between subjects with and without type 2 diabetes, independently of obesity status. J Thromb Thrombolysis. 2014;37(4):455–63. doi:10.1007/s11239-013-1000-2.CrossRefPubMed

21.

Strano A, Davi G, Patrono C. In vivo platelet activation in diabetes mellitus. Semin Thromb Hemost. 1991;17(4):422–5. doi:10.1055/s-2007-1002648.CrossRefPubMed

22.

Preston RA, Jy W, Jimenez JJ, Mauro LM, Horstman LL, Valle M, et al. Effects of severe hypertension on endothelial and platelet microparticles. Hypertension. 2003;41(2):211–7.CrossRefPubMed

23.

Lacroix R, Dignat-George F. Microparticles as a circulating source of procoagulant and fibrinolytic activities in the circulation. Thromb Res. 2012;129 Suppl 2:S27–9. doi:10.1016/j.thromres.2012.02.025.CrossRefPubMed

24.

Nielsen CT, Ostergaard O, Johnsen C, Jacobsen S, Heegaard NH. Distinct features of circulating microparticles and their relationship to clinical manifestations in systemic lupus erythematosus. Arthritis Rheum. 2011;63(10):3067–77. doi:10.1002/art.30499.CrossRefPubMed

25.

Dignat-George F, Camoin-Jau L, Sabatier F, Arnoux D, Anfosso F, Bardin N, et al. Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome. Thromb Haemost. 2004;91(4):667–73. doi:10.1267/THRO04040667.PubMed

26.

Wun T, Paglieroni T, Tablin F, Welborn J, Nelson K, Cheung A. Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia. J Lab Clin Med. 1997;129(5):507–16.CrossRefPubMed

27.

Lacroix R, Plawinski L, Robert S, Doeuvre L, Sabatier F. Martinez de Lizarrondo S et al. Leukocyte- and endothelial-derived microparticles: a circulating source for fibrinolysis. Haematologica. 2012;97(12):1864–72. doi:10.3324/haematol.2012.066167.CrossRefPubMedPubMedCentral

28.

Marques FK, Campos FM, Filho OA, Carvalho AT, Dusse LM, Gomes KB. Circulating microparticles in severe preeclampsia. Clin Chim Acta. 2012;414:253–8. doi:10.1016/j.cca.2012.09.023.CrossRefPubMed

29.

Gonzalez-Quintero VH, Smarkusky LP, Jimenez JJ, Mauro LM, Jy W, Hortsman LL, et al. Elevated plasma endothelial microparticles: preeclampsia versus gestational hypertension. Am J Obstet Gynecol. 2004;191(4):1418–24. doi:10.1016/j.ajog.2004.06.044.CrossRefPubMed

30.

Vanwijk MJ, Svedas E, Boer K, Nieuwland R, Vanbavel E, Kublickiene KR. Isolated microparticles, but not whole plasma, from women with preeclampsia impair endothelium-dependent relaxation in isolated myometrial arteries from healthy pregnant women. Am J Obstet Gynecol. 2002;187(6):1686–93.CrossRefPubMed

31.

Lok CA, Van Der Post JA, Sargent IL, Hau CM, Sturk A, Boer K, et al. Changes in microparticle numbers and cellular origin during pregnancy and preeclampsia. Hypertens Pregnancy. 2008;27(4):344–60. doi:10.1080/10641950801955733.CrossRefPubMed

32.

Bretelle F, Sabatier F, Desprez D, Camoin L, Grunebaum L, Combes V, et al. Circulating microparticles: a marker of procoagulant state in normal pregnancy and pregnancy complicated by preeclampsia or intrauterine growth restriction. Thromb Haemost. 2003;89(3):486–92. doi:10.1267/THRO03030486.PubMed

33.

Mikhailova VA, Ovchinnikova OM, Zainulina MS, Sokolov DI, Sel’kov SA. Detection of microparticles of leukocytic origin in the peripheral blood in normal pregnancy and preeclampsia. Bull Exp Biol Med. 2014;157(6):751–6. doi:10.1007/s10517-014-2659-x.CrossRefPubMed

34.

LeFevre ML. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;161(11):819–26. doi:10.7326/M14-1884.CrossRefPubMed

35.

Roberts JM, Escudero C. The placenta in preeclampsia. Pregnancy Hypertens. 2012;2(2):72–83. doi:10.1016/j.preghy.2012.01.001.PubMedPubMedCentral

36.

Meekins JW, Pijnenborg R, Hanssens M, McFadyen IR, van Asshe A. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol. 1994;101(8):669–74.CrossRefPubMed

37.

Roberts JM, Redman CW. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet. 1993;341(8858):1447–51.CrossRefPubMed

38.

Zhou Y, Damsky CH, Fisher SJ. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? J Clin Invest. 1997;99(9):2152–64. doi:10.1172/JCI119388.CrossRefPubMedPubMedCentral

39.•

Zhou Y, Damsky CH, Chiu K, Roberts JM, Fisher SJ. Preeclampsia is associated with abnormal expression of adhesion molecules by invasive cytotrophoblasts. J Clin Invest. 1993;91(3):950–60. doi:10.1172/JCI116316. An article that describes the role of trophoblast derived vesicles in remodeling of spiral arteries in normal and pathological conditions.CrossRefPubMedPubMedCentral

40.

Caniggia I, Winter J, Lye SJ, Post M. Oxygen and placental development during the first trimester: implications for the pathophysiology of pre-eclampsia. Placenta. 2000;21(Suppl A):S25–30.CrossRefPubMed

41.

Redman CW, Tannetta DS, Dragovic RA, Gardiner C, Southcombe JH, Collett GP, et al. Review: does size matter? Placental debris and the pathophysiology of pre-eclampsia. Placenta. 2012;33(Suppl):S48–54. doi:10.1016/j.placenta.2011.12.006.CrossRefPubMed

42.

Salomon C, Yee SW, Mitchell MD, Rice GE. The possible role of extravillous trophoblast-derived exosomes on the uterine spiral arterial remodeling under both normal and pathological conditions. Biomed Res Int. 2014;2014:693157. doi:10.1155/2014/693157.CrossRefPubMedPubMedCentral

43.

Salomon C, Ryan J, Sobrevia L, Kobayashi M, Ashman K, Mitchell M, et al. Exosomal signaling during hypoxia mediates microvascular endothelial cell migration and vasculogenesis. PLoS One. 2013;8(7), e68451. doi:10.1371/journal.pone.0068451.CrossRefPubMedPubMedCentral

44.

Salomon C, Kobayashi M, Ashman K, Sobrevia L, Mitchell MD, Rice GE. Hypoxia-induced changes in the bioactivity of cytotrophoblast-derived exosomes. PLoS One. 2013;8(11), e79636. doi:10.1371/journal.pone.0079636.CrossRefPubMedPubMedCentral

45.

Harris LK, Smith SD, Keogh RJ, Jones RL, Baker PN, Knofler M, et al. Trophoblast- and vascular smooth muscle cell-derived MMP-12 mediates elastolysis during uterine spiral artery remodeling. Am J Pathol. 2010;177(4):2103–15. doi:10.2353/ajpath.2010.100182.CrossRefPubMedPubMedCentral

46.

Knight M, Redman CW, Linton EA, Sargent IL. Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre-eclamptic pregnancies. Br J Obstet Gynaecol. 1998;105(6):632–40.CrossRefPubMed

47.•

Germain SJ, Sacks GP, Sooranna SR, Sargent IL, Redman CW. Systemic inflammatory priming in normal pregnancy and preeclampsia: the role of circulating syncytiotrophoblast microparticles. J Immunol. 2007;178(9):5949–56. An article that describes the proteomic anaylsis of trophoblast derived vesicles.CrossRefPubMed

48.

Goswami D, Tannetta DS, Magee LA, Fuchisawa A, Redman CW, Sargent IL, et al. Excess syncytiotrophoblast microparticle shedding is a feature of early-onset pre-eclampsia, but not normotensive intrauterine growth restriction. Placenta. 2006;27(1):56–61. doi:10.1016/j.placenta.2004.11.007.CrossRefPubMed

49.

Baig S, Lim JY, Fernandis AZ, Wenk MR, Kale A, Su LL, et al. Lipidomic analysis of human placental syncytiotrophoblast microvesicles in adverse pregnancy outcomes. Placenta. 2013;34(5):436–42. doi:10.1016/j.placenta.2013.02.004.CrossRefPubMed

50.

Baig S, Kothandaraman N, Manikandan J, Rong L, Ee KH, Hill J, et al. Proteomic analysis of human placental syncytiotrophoblast microvesicles in preeclampsia. Clin Proteomics. 2014;11(1):40. doi:10.1186/1559-0275-11-40.CrossRefPubMedPubMedCentral

51.

Leung DN, Smith SC, To KF, Sahota DS, Baker PN. Increased placental apoptosis in pregnancies complicated by preeclampsia. Am J Obstet Gynecol. 2001;184(6):1249–50. doi:10.1067/mob.2001.112906.CrossRefPubMed

52.•

Chen Y, Huang Y, Jiang R, Teng Y. Syncytiotrophoblast-derived microparticle shedding in early-onset and late-onset severe pre-eclampsia. Int J Gynaecol Obstet. 2012;119(3):234–8. doi:10.1016/j.ijgo.2012.07.010. This article describes the effect of macrohpage vesicles on production of placental inflammatory cytokines.CrossRefPubMed

53.

Lu J, Zhou WH, Ren L, Zhang YZ. CXCR4, CXCR7, and CXCL12 are associated with trophoblastic cells apoptosis and linked to pathophysiology of severe preeclampsia. Exp Mol Pathol. 2015;100(1):184–91. doi:10.1016/j.yexmp.2015.12.013.CrossRefPubMed

54.

Zhou Y, Gormley MJ, Hunkapiller NM, Kapidzic M, Stolyarov Y, Feng V, et al. Reversal of gene dysregulation in cultured cytotrophoblasts reveals possible causes of preeclampsia. J Clin Invest. 2013;123(7):2862–72. doi:10.1172/JCI66966.CrossRefPubMedPubMedCentral

55.

Holder BS, Jones T, Sancho Shimizu V, Rice TF, Donaldson B, Bouqueau M, et al. Macrophage exosomes induce placental inflammatory cytokines: a novel mode of maternal-placental messaging. Traffic. 2015. doi:10.1111/tra.12352.

56.

Abrahams VM, Kim YM, Straszewski SL, Romero R, Mor G. Macrophages and apoptotic cell clearance during pregnancy. Am J Reprod Immunol. 2004;51(4):275–82. doi:10.1111/j.1600-0897.2004.00156.x.CrossRefPubMed

57.•

Tannetta DS, Hunt K, Jones CI, Davidson N, Coxon CH, Ferguson D, et al. Syncytiotrophoblast extracellular vesicles from pre-eclampsia placentas differentially affect platelet function. PLoS One. 2015;10(11), e0142538. doi:10.1371/journal.pone.0142538. This article describes the effect of circulatory vesicles on monocytes in preeclampsia.CrossRefPubMedPubMedCentral

58.

Cockell AP, Learmont JG, Smarason AK, Redman CW, Sargent IL, Poston L. Human placental syncytiotrophoblast microvillous membranes impair maternal vascular endothelial function. Br J Obstet Gynaecol. 1997;104(2):235–40.CrossRefPubMed

59.

Messerli M, May K, Hansson SR, Schneider H, Holzgreve W, Hahn S, et al. Feto-maternal interactions in pregnancies: placental microparticles activate peripheral blood monocytes. Placenta. 2010;31(2):106–12. doi:10.1016/j.placenta.2009.11.011.CrossRefPubMed

60.

Sokolov DI, Ovchinnikova OM, Korenkov DA, Viknyanschuk AN, Benken KA, Onokhin KV, et al. Influence of peripheral blood microparticles of pregnant women with preeclampsia on the phenotype of monocytes. Transl Res. 2014. doi:10.1016/j.trsl.2014.11.009.PubMed

61.

Southcombe J, Tannetta D, Redman C, Sargent I. The immunomodulatory role of syncytiotrophoblast microvesicles. PLoS One. 2011;6(5), e20245. doi:10.1371/journal.pone.0020245.CrossRefPubMedPubMedCentral

62.

Tong M, Chamley LW. Placental extracellular vesicles and feto-maternal communication. Cold Spring Harb Perspect Med. 2015;5(3):a023028. doi:10.1101/cshperspect.a023028.CrossRefPubMed

63.

Gustafson CM, Shepherd AJ, Miller VM, Jayachandran M. Age- and sex-specific differences in blood-borne microvesicles from apparently healthy humans. Biol Sex Differ. 2015;6:10. doi:10.1186/s13293-015-0028-8.CrossRefPubMedPubMedCentral

64.

Dragovic RA, Southcombe JH, Tannetta DS, Redman CW, Sargent IL. Multicolor flow cytometry and nanoparticle tracking analysis of extracellular vesicles in the plasma of normal pregnant and pre-eclamptic women. Biol Reprod. 2013;89(6):151. doi:10.1095/biolreprod.113.113266.CrossRefPubMed

65.

Lok CA, Nieuwland R, Sturk A, Hau CM, Boer K, Vanbavel E, et al. Microparticle-associated P-selectin reflects platelet activation in preeclampsia. Platelets. 2007;18(1):68–72. doi:10.1080/09537100600864285.CrossRefPubMed

66.

Meziani F, Tesse A, David E, Martinez MC, Wangesteen R, Schneider F, et al. Shed membrane particles from preeclamptic women generate vascular wall inflammation and blunt vascular contractility. Am J Pathol. 2006;169(4):1473–83. doi:10.2353/ajpath.2006.051304.CrossRefPubMedPubMedCentral

67.

Alijotas-Reig J, Palacio-Garcia C, Farran-Codina I, Ruiz-Romance M, Llurba E, Vilardell-Tarres M. Circulating cell-derived microparticles in severe preeclampsia and in fetal growth restriction. Am J Reprod Immunol. 2012;67(2):140–51. doi:10.1111/j.1600-0897.2011.01072.x.CrossRefPubMed

68.

Tesse A, Meziani F, David E, Carusio N, Kremer H, Schneider F, et al. Microparticles from preeclamptic women induce vascular hyporeactivity in vessels from pregnant mice through an overproduction of NO. Am J Physiol Heart Circ Physiol. 2007;293(1):H520–5. doi:10.1152/ajpheart.01094.2006.CrossRefPubMed

69.

VanWijk MJ, Nieuwland R, Boer K, van der Post JA, VanBavel E, Sturk A. Microparticle subpopulations are increased in preeclampsia: possible involvement in vascular dysfunction? Am J Obstet Gynecol. 2002;187(2):450–6.CrossRefPubMed

70.

Holthe MR, Lyberg T, Staff AC, Berge LN. Leukocyte-platelet interaction in pregnancies complicated with preeclampsia. Platelets. 2005;16(2):91–7. doi:10.1080/09537100400004355.CrossRefPubMed

71.

Lok CA, Jebbink J, Nieuwland R, Faas MM, Boer K, Sturk A, et al. Leukocyte activation and circulating leukocyte-derived microparticles in preeclampsia. Am J Reprod Immunol. 2009;61(5):346–59. doi:10.1111/j.1600-0897.2009.00701.x.CrossRefPubMed

72.

Campello E, Spiezia L, Radu CM, Dhima S, Visentin S, Valle FD, et al. Circulating microparticles in umbilical cord blood in normal pregnancy and pregnancy with preeclampsia. Thromb Res. 2015. doi:10.1016/j.thromres.2015.05.029.

73.

Lurie S, Frenkel E, Tuvbin Y. Comparison of the differential distribution of leukocytes in preeclampsia versus uncomplicated pregnancy. Gynecol Obstet Investig. 1998;45(4):229–31.CrossRef

74.

Maurus CF, Schneider MK, Schmidt D, Zund G, Seebach JD. Activation of human microvascular endothelial cells with TNF-alpha and hypoxia/reoxygenation enhances NK-cell adhesion, but not NK-Cytotoxicity. Transplantation. 2006;81(8):1204–11. doi:10.1097/01.tp.0000205175.53938.bd.CrossRefPubMed

75.

Holder BS, Tower CL, Jones CJ, Aplin JD, Abrahams VM. Heightened pro-inflammatory effect of preeclamptic placental microvesicles on peripheral blood immune cells in humans. Biol Reprod. 2012;86(4):103. doi:10.1095/biolreprod.111.097014.CrossRefPubMed

76.

Joerger-Messerli MS, Hoesli IM, Rusterholz C, Lapaire O. Stimulation of monocytes by placental microparticles involves toll-like receptors and nuclear factor kappa-light-chain-enhancer of activated B cells. Front Immunol. 2014;5:173. doi:10.3389/fimmu.2014.00173.CrossRefPubMedPubMedCentral

77.

Leroyer AS, Anfosso F, Lacroix R, Sabatier F, Simoncini S, Njock SM, et al. Endothelial-derived microparticles: biological conveyors at the crossroad of inflammation, thrombosis and angiogenesis. Thromb Haemost. 2010;104(3):456–63. doi:10.1160/TH10-02-0111.CrossRefPubMed

78.

Sarrel PM, Lindsay DC, Poole-Wilson PA, Collins P. Hypothesis: inhibition of endothelium-derived relaxing factor by haemoglobin in the pathogenesis of pre-eclampsia. Lancet. 1990;336(8722):1030–2.CrossRefPubMed

79.

Fish R. The HELLP syndrome: case report and review of the literature. J Emerg Med. 1993;11(2):169–74.CrossRefPubMed

80.

Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007;115(10):1285–95. doi:10.1161/CIRCULATIONAHA.106.652859.PubMed

81.

Choi JW, Im MW, Pai SH. Nitric oxide production increases during normal pregnancy and decreases in preeclampsia. Ann Clin Lab Sci. 2002;32(3):257–63.PubMed

82.

Easterling TR, Benedetti TJ, Schmucker BC, Millard SP. Maternal hemodynamics in normal and preeclamptic pregnancies: a longitudinal study. Obstet Gynecol. 1990;76(6):1061–9.PubMed

83.

Petrozella L, Mahendroo M, Timmons B, Roberts S, McIntire D, Alexander JM. Endothelial microparticles and the antiangiogenic state in preeclampsia and the postpartum period. Am J Obstet Gynecol. 2012;20(2):140.e20–6. doi:10.1016/j.ajog.2012.06.011.CrossRef

84.

Jimenez JJ, Jy W, Mauro LM, Soderland C, Horstman LL, Ahn YS. Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb Res. 2003;109(4):175–80.CrossRefPubMed

85.

Dignat-George F, Boulanger CM. The many faces of endothelial microparticles. Arterioscler Thromb Vasc Biol. 2011;31(1):27–33. doi:10.1161/ATVBAHA.110.218123.CrossRefPubMed

86.

Kapustin AN, Shanahan CM. Calcium regulation of vascular smooth muscle cell-derived matrix vesicles. Trends Cardiovasc Med. 2012;22(5):133–7. doi:10.1016/j.tcm.2012.07.009.CrossRefPubMed

87.

Rosenkranz A, Hiden M, Leschnik B, Weiss EC, Schlembach D, Lang U, et al. Calibrated automated thrombin generation in normal uncomplicated pregnancy. Thromb Haemost. 2008;99(2):331–7. doi:10.1160/TH07-05-0359.PubMed

88.

Bonnar J, McNicol GP, Douglas AS. Coagulation and fibrinolytic systems in pre-eclampsia and eclampsia. Br Med J. 1971;2(5752):12–6.CrossRefPubMedPubMedCentral

89.

Brown MA. The physiology of pre-eclampsia. Clin Exp Pharmacol Physiol. 1995;22(11):781–91.CrossRefPubMed

90.

Reith A, Booth NA, Moore NR, Cruickshank DJ, Bennett B. Plasminogen activator inhibitors (PAI-1 and PAI-2) in normal pregnancies, pre-eclampsia and hydatidiform mole. Br J Obstet Gynaecol. 1993;100(4):370–4.CrossRefPubMed

91.

Brodsky SV, Malinowski K, Golightly M, Jesty J, Goligorsky MS. Plasminogen activator inhibitor-1 promotes formation of endothelial microparticles with procoagulant potential. Circulation. 2002;106(18):2372–8.CrossRefPubMed

92.

Chu AJ. Tissue factor, blood coagulation, and beyond: an overview. Int J Inflamm. 2011;2011:367284. doi:10.4061/2011/367284.CrossRef

93.

Teng YC, Lin QD, Lin JH, Ding CW, Zuo Y. Coagulation and fibrinolysis related cytokine imbalance in preeclampsia: the role of placental trophoblasts. J Perinat Med. 2009;37(4):343–8. doi:10.1515/JPM.2009.060.CrossRefPubMed

94.

Aharon A, Brenner B, Katz T, Miyagi Y, Lanir N. Tissue factor and tissue factor pathway inhibitor levels in trophoblast cells: implications for placental hemostasis. Thromb Haemost. 2004;92(4):776–86. doi:10.1267/THRO04040776.PubMed

95.

Teng Y, Jiang R, Lin Q, Ding C, Ye Z. The relationship between plasma and placental tissue factor, and tissue factor pathway inhibitors in severe pre-eclampsia patients. Thromb Res. 2010;126(1):e41–5. doi:10.1016/j.thromres.2010.02.012.CrossRefPubMed

96.

Gardiner C, Tannetta DS, Simms CA, Harrison P, Redman CW, Sargent IL. Syncytiotrophoblast microvesicles released from pre-eclampsia placentae exhibit increased tissue factor activity. PLoS One. 2011;6(10), e26313. doi:10.1371/journal.pone.0026313.CrossRefPubMedPubMedCentral

97.

Zhang Y, Hua Z, Zhang K, Meng K, Hu Y. Therapeutic effects of anticoagulant agents on preeclampsia in a murine model induced by phosphatidylserine/phosphatidylcholine microvesicles. Placenta. 2009;30(12):1065–70. doi:10.1016/j.placenta.2009.09.004.CrossRefPubMed

Title: Preeclampsia and Extracellular Vesicles
Authors: Sarwat I. Gilani
Tracey L. Weissgerber
Vesna D. Garovic
Muthuvel Jayachandran
Publication date: 01-09-2016
Publisher: Springer US
Published in: Current Hypertension Reports / Issue 9/2016
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-016-0678-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Preeclampsia and Extracellular Vesicles

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page